Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01514591 · ClinicalTrials.gov registry record

Thromboelastography in Non-elective Cesarean Delivery

A clinical trial of Bleeding, sponsored by Stanford University.

Completed
Registry status
33
Enrollment target
1
Study location

NCT01514591: Completed study of Bleeding, sponsored by Stanford University.

NCT01514591 is a study of Bleeding that has completed, run by Stanford University. The registered enrollment target is 33 participants, below the 1,483-participant average among 23 other Bleeding trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01514591, a study of Bleeding, has completed, sponsored by Stanford University.

COMPLETED
Registry status
33 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to assess the coagulation changes that occur in laboring patients undergoing non-elective (intrapartum)Cesarean delivery using thromboelastography (TEG). We will compare coagulation data to assess potential coagulation changes associated with hemoglobin changes before and after surgery, and related to estimated blood loss.

Primary Outcome

This study will allow us to collect more information about the hemostatic effects that occur during non-elective Cesarean delivery. This information will add to current knowledge base (which we have published) about coagulation changes in the peripartum period in patients undergoing non-elective Cesarean section.

Conditions Studied

Study Locations (1)

California

  • Lucile Packard Children's Hospital - Stanford

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2011-08
Est. Completion 2013-06
Stanford University

1,744 total trials

What the finished NCT01514591 record still lists

NCT01514591 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,483-participant average among 23 other Bleeding trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Bleeding appearing as the primary indexed condition, and to 0 interventions.

NCT01514591 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01514591 about?

NCT01514591 is a clinical study titled "Thromboelastography in Non-elective Cesarean Delivery". The purpose of the study is to assess the coagulation changes that occur in laboring patients undergoing non-elective (intrapartum)Cesarean delivery using thromboelastography (TEG). We will compare coagulation data to assess potential coagulation changes associated with hemoglobin changes before and...

What is the current status of trial NCT01514591?

This trial is currently completed. The enrollment target is 33 participants. The study started on 2011-08. Estimated completion is 2013-06.

What conditions does trial NCT01514591 study?

This clinical trial studies the following conditions: Bleeding.

Who is sponsoring clinical trial NCT01514591?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01514591 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bleeding

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01514591's enrollment target sits among peer trials

33 24th of 23 the lowest of 23 other Bleeding trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bleeding trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02861898 · 33 participants · Phase 1

    Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

  • NCT04871607 · 33 participants · Phase 2

    Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

  • NCT05071937 · 33 participants · Phase 2

    ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

  • NCT05168618 · 33 participants · Phase 2

    Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01514591, the US trial registry maintained by the National Library of Medicine. NCT01514591 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.